satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Arne Kolstad,* Tim Illidge,* Nils Bolstad, Signe Spetalen, Ulf Madsbu, Caroline Stokke, Johan Blakkisrud, Ayca Løndalen, Noelle O’Rourke, Matthew Beasley, Wojciech Jurczak, Unn-Merete Fagerli, Michal Kaščák, Mike Bayne, Aleš Obr, Jostein Dahle, Lisa Rojkjaer, Veronique Pascal, and Harald Holte Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway; University of Manchester, National Institutes of Health Research Manchester Biomedical Research Centre, Christie Hospital, Manchester, United Kingdom; Department of Medical Biochemistry, Oslo University Hospital, Radiumhospitalet, Oslo, Norway; Department of Pathology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway; Department of Radiology and Nuclear Medicine, Department of Diagnostic Physics, and Department of Nuclear Medicine, Oslo University Hospital, Radiumhospitalet, Oslo, Norway; BeatsonWest of Scotland Cancer Centre, Glasgow, United Kingdom; Bristol Cancer Institute, Bristol, United Kingdom; Maria Sklodowska-Curie National Institute of Oncology, Kraków, Poland; St. Olav’s Hospital and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, Ostrava University, Ostrava, Czech Republic; Dorset Cancer Centre, Poole, United Kingdom; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic; and Nordic Nanovector ASA, Oslo, Norway